Rhizen's cancer drug Umbralisib gets USFDA nod: Alembic Pharma

Alembic Pharma on Tuesday said its associate company Rhizen Pharmaceuticals AG's product Umbralisib, which was licensed to TG Therapeutics, has received approval from the US health regulator the drug for the treatment of certain forms of cancer.In a regulatory filing, Alembic Pharma said Rhizen Pharmaceuticals' Umbralisib, which was licensed to TG Therapeutics has secured the United States Food and Drug Administration (USFDA) accelerated approval for the treatment of adult patients.
Read more...

;